An observational study in Rhabdomyolysis-Induced Renal Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. While ECRT techniques are commonly used in this situation, their actual effectiveness in eliminating myoglobin and improving renal function remains poorly established. In particular, mid-cut-off membranes, developed to better remove intermediate molecular weight molecules, could improve renal prognosis. This study aims to evaluate, using retrospective clinical data, the impact of these techniques on renal recovery.
40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.
This study's planned enrollment of 100 is below the median of 150 across 23 observational studies indexed under Rhabdomyolysis.
Browse Rhabdomyolysis studies →University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patient (≥18 years) with confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Total duration of dependence on extrarenal purification (ERP) (in days)
Total duration of dependence on ERC (in days), defined as the number of days between initiation and discontinuation of any form of dialysis.
Time frame: up to 15 month
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →